Promoting equitable access to hepatitis C treatment for Indo-Chinese injecting drug users

被引:6
作者
Coupland, Heidi [1 ,2 ]
Day, Carolyn [3 ]
Levy, Miriam T. [4 ,5 ]
Maher, Lisa [2 ]
机构
[1] Univ New S Wales, St Vincents Med Ctr, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia
[2] Univ New S Wales, Sch Publ Hlth & Community Med, Sydney, NSW, Australia
[3] Univ Sydney, Cent Clin Sch, Sydney Med Sch, Sydney, NSW 2006, Australia
[4] Univ New S Wales, S Western Sydney Area Hlth Serv, Sydney, NSW, Australia
[5] Univ New S Wales, Fac Med, Sydney, NSW, Australia
关键词
injecting drug user; hepatitis C treatment; marginalisation; cultural diversity; VIRUS HCV INFECTION; BLOOD-BORNE VIRUSES; ETHNIC-VIETNAMESE; RISK BEHAVIORS; BARRIERS; THERAPY; EPIDEMIOLOGY; MELBOURNE; KNOWLEDGE; ATTITUDES;
D O I
10.1071/HE09234
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Issue addressed: Increasing the uptake of hepatitis C treatment by injecting drug users (IDUs) is a key strategy in addressing the escalating disease burden of chronic hepatitis C virus (HCV) infection in Australia. Little is known about barriers to treatment uptake among culturally diverse groups of IDUs. Indo-Chinese IDUs represent a marginalised group with high rates of incident and prevalent HCV infection. Methods: An ethnographic study was conducted to explore barriers to HCV treatment uptake experienced by Indo-Chinese IDUs and inform the development of policies and practices that promote access to treatment. Following a baseline interview, participants (n=23) received a brief intervention about HCV treatment and an offer of facilitated referral to a tertiary liver clinic. Follow-up interviews were conducted three and six months post intervention, to explore decision-making about treatment-seeking and experiences accessing the clinic. Results: While 'getting rid of' HCV was regarded as highly desirable, only three participants were assessed for treatment. For most participants, seeking treatment was not seen as feasible given social and structural barriers related to their drug use, lack of resources and support. Institutional barriers included the clinic's administrative procedures, limited flexibility and apparent reluctance to consider current IDUs suitable candidates for treatment. Conclusions: Resources and support, flexible, low threshold approaches to assessment and a willingness to provide treatment to current IDUs, would promote equitable access to treatment among these groups.
引用
收藏
页码:234 / 240
页数:7
相关论文
共 50 条
  • [31] HEPATITIS C VIRUS ANTIBODY STATUS, SOCIODEMOGRAPHIC CHARACTERISTICS, AND RISK BEHAVIOUR AMONG INJECTING DRUG USERS IN CROATIA
    Cavlek, Tatjana Vilibic
    Maric, Jelena
    Katicic, Ljiljana
    Kolaric, Branko
    [J]. CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH, 2011, 19 (01) : 26 - 29
  • [32] Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow
    McDonald, Scott A.
    Hutchinson, Sharon J.
    Cameron, Sheila O.
    Innes, Hamish A.
    McLeod, Allan
    Goldberg, David J.
    [J]. INTERNATIONAL JOURNAL OF DRUG POLICY, 2012, 23 (05) : 353 - 357
  • [33] Clinical trial: a primary-care-based model for the delivery of anti-viral treatment to injecting drug users infected with hepatitis C
    Jack, K.
    Willott, S.
    Manners, J.
    Varnam, M. A.
    Thomson, B. J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (01) : 38 - 45
  • [34] Access to Treatment of Hepatitis C in Prison Inmates
    Strock, Paul
    Mossong, Joel
    Hawotte, Karine
    Arendt, Vic
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (06) : 1325 - 1330
  • [35] Access to Treatment of Hepatitis C in Prison Inmates
    Paul Strock
    Joël Mossong
    Karine Hawotte
    Vic Arendt
    [J]. Digestive Diseases and Sciences, 2009, 54
  • [36] The comparison of chronic hepatitis C treatment outcome between intravenous drug users and non-intravenous drug users
    Bojovic, K.
    Simonovic, J.
    Katanic, N.
    Milosevic, I.
    Pesic, I.
    Delic, D.
    Svirtlih, N.
    Jevtovic, D. J.
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2013, 67 (06) : 517 - 520
  • [37] Decline in incidence of HIV and hepatitis C virus infection among injecting drug users in Amsterdam; evidence for harm reduction?
    de Vos, Anneke S.
    van der Helm, Jannie J.
    Matser, Amy
    Prins, Maria
    Kretzschmar, Mirjam E. E.
    [J]. ADDICTION, 2013, 108 (06) : 1070 - 1081
  • [38] Characterization of Occult Hepatitis B Infection Among Injecting Drug Users in Tehran, Iran
    Asli, Maryam
    Kandelouei, Tahmineh
    Rahimyan, Koroush
    Davoodbeglou, Foad
    Vaezjalali, Maryam
    [J]. HEPATITIS MONTHLY, 2016, 16 (03)
  • [39] Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study
    Kyriakos Souliotis
    Eirini Agapidaki
    Manto Papageorgiou
    Niki Voudouri
    Xenophon Contiades
    [J]. International Journal for Equity in Health, 16
  • [40] Access to treatment for Hepatitis C among injection drug users: results from the cross-sectional HOPE IV study
    Souliotis, Kyriakos
    Agapidaki, Eirini
    Papageorgiou, Manto
    Voudouri, Niki
    Contiades, Xenophon
    [J]. INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH, 2017, 16